If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
588.00    0.00 (0.00%)
Bid:
586.00
Ask:
590.00
Spread: 4.00 (0.683%)
Market Cap: £512.29m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Interim Management Statement

21 Jul 2015 07:00

RNS Number : 5569T
Victrex PLC
21 July 2015
 



 

 

 

 

 

 

21 July 2015

 

Victrex plc - Interim Management Statement

 

"Solid trading and acquisition of Kleiss Gears"

 

Victrex plc, an innovative world leader in high performance polymer solutions, today announces its Interim Management Statement for the period 1 April 2015 to 30 June 2015 (Q3) and the acquisition of Kleiss Gears Incorporated for a cash consideration of approximately $6m.

 

Victrex saw solid trading against tougher comparatives during Q3, with our performance reflecting continuing growth across our industrial markets, which is offsetting sales to Oil & Gas and a lower contribution from our Invibio medical business. Third quarter Group revenue of £64.5m was flat compared to the prior year period (Q3 2014: £64.2m) and slightly ahead in constant currency, with third quarter Group sales volume of 1,070 tonnes 17% ahead of the prior year (Q3 2014: 911 tonnes). Year to date Group sales volume of 3,098 tonnes is 24% ahead of the prior year (YTD 2014: 2,495 tonnes).

 

Within Victrex Polymer Solutions (VPS), Consumer Electronics volumes remain strong and, as previously communicated, we expect volumes from the current opportunity to continue through our 2016 financial year.

 

In our Invibio medical business, the sales improvement trend we saw in Q2 did not continue as we anticipated during Q3. Overall sales were down during the quarter, driven lower by the continued effects of consolidation in the US medical device industry. However, outside of the US, sales in Europe and emerging markets remain positive. On a full year basis, we now anticipate Invibio revenue will be lower than 2014. Our expectation is for full year sales to decline by a broadly similar level to the 4% reduction seen in the first half year.

 

All of our new product platforms and adoption programmes continue to make positive progress, including those in medical for PEEK-OPTIMA® HA-Enhanced (Spine), Dental, Trauma and Knee.

 

Acquisition of Kleiss Gears

Victrex is pleased to announce the acquisition of Kleiss Gears, a US based polymer gears' manufacturer, for approximately $6m (£3.8m) in cash.

 

Kleiss has over 20 years' experience of unique design and precision moulding capability in gears, and will benefit from Victrex's materials know-how, existing customer relationships and global commercial reach. Kleiss has early stage commercialisation of PEEK gear programmes, alongside the rest of its mainly industrial focused gears business.

 

The acquisition is in line with Victrex's strategy of moving further downstream and investing in growth acceleration opportunities for its pipeline projects. It offers the opportunity to accelerate Victrex's PEEK gear proposition to the automotive industry, in line with our aim to double the amount of PEEK volume in cars over the medium term.

 

For its 2014 financial year, Kleiss had revenues of approximately $4m and employed 26 people.

 

Outlook

For the year as a whole, whilst challenges continue in the Oil & Gas market and in improving Invibio's performance, our overall momentum remains positive and we still expect to fully overcome the impact of foreign currency. Consequently, and reflecting our balanced portfolio, Victrex remains well positioned to deliver profit progress over the full year.

 

Cash generation remains healthy and there have been no significant changes to the Group's financial position since our interim results announcement.

 

 

Enquiries:

 

Victrex plc:

Andrew Hanson, Head of Investor Relations & Communications +44 (0) 1253 898121

Louisa Burdett, Group Finance Director +44 (0) 1253 897700

David Hummel, Chief Executive +44 (0) 1253 897700

 

Pendomer Communications:

Charles Armitstead +44 (0) 203 603 5220

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions focused on the Aerospace, Automotive, Electronics, Energy and Medical markets. Every day, millions of people rely on products or applications which contain our polymers, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 35 years' experience, we are investing in technical excellence to deliver leading edge solutions to our customers and our markets, and to drive value for our shareholders. Find out more at www.victrexplc.com

 

Investor and analyst call:

A call for investors and analysts will be held today, Tuesday 21 July at 08.00am UK time. For dial in details please contact Laura Stewart at Pendomer Communications: laura.stewart@pendomer.com or +44 (0) 203 603 5229.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSEASXEAEDSEFF
Date   Source Headline
7th Jan 20132:02 pmRNSAnnual Financial Report
7th Jan 201312:37 pmRNSHolding(s) in Company
28th Dec 201212:00 pmRNSTotal Voting Rights
19th Dec 20121:09 pmRNSDirector/PDMR Shareholding
18th Dec 20124:40 pmRNSDirector/PDMR Shareholding
18th Dec 201210:08 amRNSHolding(s) in Company
12th Dec 20124:08 pmRNSDirector/PDMR Shareholding
11th Dec 20127:00 amRNSFinal Results
3rd Dec 20122:23 pmRNSBlocklisting Interim Review
30th Nov 20122:05 pmRNSTotal Voting Rights
20th Nov 201212:18 pmRNSDirector/PDMR Shareholding
1st Nov 201210:34 amRNSTotal Voting Rights
30th Oct 201210:28 amRNSHolding(s) in Company
18th Oct 20124:07 pmRNSDirector/PDMR Shareholding
16th Oct 201212:03 pmRNSHolding(s) in Company
16th Oct 20127:00 amRNSSite Visit
10th Oct 201210:33 amRNSHolding(s) in Company
4th Oct 20127:00 amRNSTrading Statement
28th Sep 20121:36 pmRNSTotal Voting Rights
28th Sep 20121:21 pmRNSHolding(s) in Company
19th Sep 201212:57 pmRNSDirector/PDMR Shareholding
31st Aug 20122:05 pmRNSTotal Voting Rights
20th Aug 201211:22 amRNSDirector/PDMR Shareholding
31st Jul 201212:19 pmRNSTotal Voting Rights
26th Jul 20127:00 amRNSInterim Management Statement
17th Jul 20123:35 pmRNSDirector/PDMR Shareholding
12th Jul 201210:41 amRNSHolding(s) in Company
29th Jun 20122:25 pmRNSTotal Voting Rights
27th Jun 20123:48 pmRNSDirector/PDMR Shareholding
20th Jun 20123:10 pmRNSDirector/PDMR Shareholding
14th Jun 20121:23 pmRNSDirector/PDMR Shareholding
1st Jun 201211:44 amRNSBlocklisting Interim Review
31st May 20122:55 pmRNSTotal Voting Rights
22nd May 20127:00 amRNSHalf Yearly Report
17th May 20123:52 pmRNSDirector/PDMR Shareholding
30th Apr 20124:26 pmRNSTotal Voting Rights
27th Apr 20127:00 amRNSManagement Change
26th Apr 20128:30 amRNSAdditional Listing
18th Apr 20124:10 pmRNSDirector/PDMR Shareholding
5th Apr 20127:00 amRNSTrading Update
30th Mar 201212:11 pmRNSTotal Voting Rights
26th Mar 201211:45 amRNSHolding(s) in Company
19th Mar 20123:06 pmRNSDirector/PDMR Shareholding
19th Mar 20127:00 amRNSManagement Change
29th Feb 20122:11 pmRNSTotal Voting Rights
20th Feb 201211:52 amRNSDirector/PDMR Shareholding
17th Feb 201210:39 amRNSHolding(s) in Company
13th Feb 201211:37 amRNSHolding(s) in Company
9th Feb 20123:25 pmRNSHolding(s) in Company
8th Feb 201210:33 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.